{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-131037","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.091724+00:00","generated_at":"2026-05-28T23:48:09.966376+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Zura Bio launches Phase 2 TibuSURE study of tibulizumab in systemic sclerosis","bullets":["TibuSURE is a global Phase 2 double-blind, placebo-controlled trial in ~80 adults with early diffuse cutaneous systemic sclerosis.","First clinical trial to target both BAFF and IL-17 pathways in SSC, using dual-antagonist antibody tibulizumab.","Primary endpoint is modified Rodnan Skin Score; key endpoints include lung function (qHRCT, FVC) and physical function (HAQ-DI, rCRISS).","Study includes 24-week efficacy period followed by a 28-week open-label extension.","First clinical site has been initiated; results expected to inform further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-131037","json":"https://secwatch.observer/filing/0001104659-24-131037.json","markdown":"https://secwatch.observer/filing/0001104659-24-131037.md","text":"https://secwatch.observer/filing/0001104659-24-131037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924131037/0001104659-24-131037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924131037/tm2431378d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:48:09.966376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}